We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Sekisui Diagnostics

PERKIN ELMER CORPORATION

PerkinElmer provides detection technologies to detect and identify diseases, imaging technologies to help visualize s... read more Featured Products: More products

Download Mobile App





PerkinElmer’s EUROIMMUN Presents Novel Ultrafast Automated Microscope and Intelligent Software for State-of-the-Art Diagnostics

By LabMedica International staff writers
Posted on 21 Jun 2021
Print article
Image: EUROPattern Microscope Live (Photo courtesy of PerkinElmer, Inc.)
Image: EUROPattern Microscope Live (Photo courtesy of PerkinElmer, Inc.)
EUROIMMUN, a PerkinElmer, Inc. (Waltham, MA; USA) company, presented its novel ultrafast automated microscope and intelligent software for state-of-the-art diagnostics at Medlab Middle East 2021.

The company’s portfolio encompasses indirect immunofluorescence assays (IFA), ELISAs, immunoblots, radioimmunoassays, chemiluminescence immunoassays (ChLIA) and molecular genetic test systems and spans over a thousand diagnostic parameters. At this year’s edition of Medlab Middle East, EUROIMMUN introduced its newly-launched EUROPattern Microscope Live (EPML), a compact immunofluorescence microscope available with the fourth generation of the company’s well-established EUROLabOffice 4.0 (ELO 4.0) laboratory management software. The combined system of hardware and software allows for ultrafast automated immunofluorescence image acquisition, pattern recognition and titer estimation as well as modern diagnostics at the screen.

Due to application of a novel laser focusing technology, the EPML acquires and interprets high quality immunofluorescence images in less than two seconds per image. The system autonomously evaluates a particularly high number of recorded immunofluorescence patterns that are indicative of the presence of certain autoantibodies, and thus point to a specific autoimmune disease, such as rheumatoid arthritis, systemic lupus erythematosus, vasculitis or autoimmune hepatitis. In addition to the positive/negative classification for a variety of different substrates, the patterns of anti-nuclear antibodies (in conformity with the International Consensus on Antinuclear Antibody Patterns) and anti-neutrophil cytoplasmic antibodies can also be recognized by leveraging deep learning algorithms. A touch screen allows easy live microscopy via multi-touch navigation and pinch-to-zoom functionality.

ELO 4.0 software further simplifies and is designed to speed up not only IIFT testing but also other laboratory diagnostics by acting as the central interface for all laboratory instruments, working places and laboratory information systems. ELO 4.0 software enables intelligent and intuitive data management as well as the seamless communication needed to provide operators with a 360-degree view of a patient’s results, including current and past findings, that can lead to a faster, more reliable diagnosis.

In addition, EUROIMMUN showcased its comprehensive test and automation portfolio of CE-marked tests for direct and indirect detection of SARS-CoV-2, including its PCR-based tests EURORealTime SARS-CoV-2 and EURORealTime SARS-CoV-2 / Influenza A / B as well as the SARS-CoV-2 Antigen ELISA.

Related Links:
PerkinElmer, Inc.

Automated ELISA-IFA-BLOT Processor AP 22
New
Gold Supplier
pHOx Analyzer
BioProfile pHOx Analyzer
New
Automated Hematology Analyzer
Celltac Alpha MEK-1301/1302
New
Automatic Specific Protein Analyzer
PA 900

Print article

Channels

Molecular Diagnostics

view channel
Image: A new method reliably detects protein changes in blood that are typical of Parkinson`s disease (Photo courtesy of Pexels)

First-Ever Blood Test Detects Parkinson’s Disease

Until now, the diagnosis of Parkinson's disease has been based primarily on typical movement disorders such as muscle stiffness, slower movements and shaking. However, the disease starts up to 20 years... Read more

Industry

view channel
Image: Fujirebio has acquired ADx NeuroSciences for 40 million Euros (Photo courtesy of Pexels)

Fujirebio Acquires ADx NeuroSciences to Speed Development of Neurodegenerative Diseases Diagnostic Tests

Fujirebio Holdings, Inc. (Tokyo, Japan) has announced the acquisition of ADx NeuroSciences (Gent, Belgium) for EUR 40 million in a deal that is expected to close in July 2022, pending the satisfaction... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.